MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection ...

Diagnostics provide the insight, but only a connected pathway turns that insight into real-world impact. That means ensuring ...

This demographic shift is placing immense strain on health and social care systems worldwide, and calls for bold, innovative ...

The White House has confirmed that the trade deal signed with the EU – which includes an overarching tariff rate of 15% on ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

In a statement, the Cambridge, Massachusetts-based company said that shipments of Elevidys (delandistrogene moxeparvovec) will restart while it continues dialogue with the FDA "on next steps in the ...

In 2023 the FDA published guidance on rare diseases. The guidance recognises that many rare diseases are serious conditions ...

Bayer's rivalry with Boehringer Ingelheim in the development of medicines for HER2-mutated non-small cell lung cancer (NSCLC) ...

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...

This approach, while embedded in clinical guidelines and workflow protocols, does not reflect the underlying biology of ...

That's the top-line finding of the latest financing report from the UK BioIndustry Association (BIA), which reveals that ...

At this year's American Society of Clinical Oncology’s Annual Meeting, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial evaluating first-line treatment in patients ...